ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Jul 24, 2024 · CIK: 1715925
Sentiment: neutral
Topics: reporting, foreign-private-issuer, press-release
TL;DR
IPA files 6-K, check press release for news.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on July 24, 2024, reporting a press release dated July 23, 2024. The filing is for the month of July 2024 and indicates the company will file annual reports under Form 20-F. The principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing serves as an update for investors regarding the company's reporting status and includes a press release, which may contain material business developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no immediate financial or operational changes disclosed.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- July 23, 2024 (date) — Date of the press release
- July 24, 2024 (date) — Filing date of the 6-K
- Kristin Taylor (person) — Signatory for the company
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of July 2024, and it includes a press release dated July 23, 2024.
Which annual report form does ImmunoPrecise Antibodies Ltd. file?
ImmunoPrecise Antibodies Ltd. files its annual reports under cover of Form 20-F.
What is the address of the registrant's principal executive office?
The address of the registrant's principal executive office is 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Who signed the report on behalf of ImmunoPrecise Antibodies Ltd.?
The report was signed by Kristin Taylor, on behalf of ImmunoPrecise Antibodies Ltd.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated July 23, 2024, is included with this 6-K filing.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-07-23 21:55:46
Filing Documents
- press_release_july_23_20.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 16KB
- 0000950170-24-085845.txt ( ) — 38KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: July 23, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer